New drug ripertamab tested for muscle weakness disease
NCT ID NCT07372807
First seen Jan 31, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This early-stage trial tests if ripertamab can safely improve daily living for people with generalized myasthenia gravis, a condition causing muscle weakness. About 20 adults will receive a single infusion of ripertamab or a placebo and be monitored for 13 weeks. The main goal is to see if symptoms improve without needing rescue therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.